Monego E T, Peixoto M do R, Jardim P C, Sousa A L, Braga V L, Moura M F
Faculdades de Medicina, Universidade Federal de Goiás, Goiânia.
Arq Bras Cardiol. 1996 Jun;66(6):343-7.
To evaluate the efficacy and tolerability of different therapies associated with diet in the treatment of hypertensive obese patients.
In a clinical study we randomly evaluated 39 hypertensive obese patients (body mass index (BMI) > or = 30 kg/m2). After 45 days of diet the patients were again randomly distributed in 3 groups and received in double blind way: group 1-hypocaloric diet+placebo; group 2-hypocaloric diet+dexfenfluramine; group 3-hypocaloric diet+spiruline+fucus+gelatin. We followed their progress during 12 weeks under medication and further 24 weeks without. We evaluated the groups comparing: weight, BMI, blood pressure and side-effects.
Twenty seven patients completed the observation. In those patients from groups 1 and 3 no changes in any of parameters were observed. In group 2 we observed a clear loss of weight (-3.8 Kg) and a fall in BMI. Blood Pressure changes were only observed in group 2 (-9.6%). The only patients to maintain weight loss after the termination of use of medicines were those from group 2. We did not observe any side-effects.
In hypertensive obese patients, when isolated diet is not enough to control weight loss, dexfenfluramine could be useful in association with a controlled diet. The drug assists in weight loss, does not promote side-effects and does not interfere in the treatment of blood pressure.
评估不同饮食疗法联合用药治疗高血压肥胖患者的疗效及耐受性。
在一项临床研究中,我们随机评估了39例高血压肥胖患者(体重指数(BMI)≥30kg/m²)。经过45天的饮食干预后,患者再次随机分为3组,并采用双盲法给药:第1组-低热量饮食+安慰剂;第2组-低热量饮食+右芬氟拉明;第3组-低热量饮食+螺旋藻+墨角藻+明胶。我们在用药12周及停药后24周对患者进行跟踪观察。我们通过比较各组的体重、BMI、血压及副作用来评估治疗效果。
27例患者完成了观察。第1组和第3组患者的各项参数均无变化。第2组患者体重明显减轻(-3.8kg),BMI下降。仅在第2组观察到血压变化(-9.6%)。停药后仍能维持体重减轻的患者仅来自第2组。我们未观察到任何副作用。
对于高血压肥胖患者,单纯饮食不足以控制体重减轻时,右芬氟拉明联合控制饮食可能有效。该药物有助于减轻体重,不产生副作用,且不干扰血压治疗。